IL6 and metabolic disease: This indicates an improvement in glucose tolerance in KD-64-treated mice compared to the obese control mice which might be connected to the anti-inflammatory effect of the tested compound and a decrease in plasma IL-6 levels, since IL-6 and its signalling path play complex roles in metabolic disorders [71].